Hummel M, Spiess B, Kentouche K, Niggemann S, Böhm C, Reuter S, Kiehl M, Mörz H, Hehlmann R, Buchheidt D
III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Germany.
J Clin Microbiol. 2006 Nov;44(11):3989-93. doi: 10.1128/JCM.00466-06. Epub 2006 Aug 30.
Invasive aspergillosis (IA), a complication with high mortality rates, especially in disseminated IA with cerebral involvement, is difficult to diagnose. Biopsy of cerebral lesions is often not feasible, and culture of Aspergillus spp. from cerebrospinal fluid (CSF) is frequently negative. New molecular methods have emerged for diagnosing IA. So far, there are only few reports of Aspergillus DNA detection in CSF. After modifying the DNA extraction protocol, we detected Aspergillus DNA in CSF samples by a previously described nested PCR assay. In six patients with hematologic malignancy and cerebral aspergillosis, CSF samples were investigated for Aspergillus DNA. IA was classified according to the EORTC/MSG 2002 criteria. Two patients each had proven, probable, and possible IA. Thirty-five CSF samples were investigated for Aspergillus DNA by nested PCR. Samples with positive results in the nested PCR assay were quantified by LightCycler PCR assay. Fourteen CSF samples showed positive results in the nested PCR assay. Of these, six samples gave positive results in real-time PCR. The range of CFU per ml was 2,154 to 63,100,000. The highest number of CFU per ml was found in a CSF sample of a patient with acute lymphocytic leukemia and probable cerebral aspergillosis. Detection of Aspergillus DNA in CSF samples is thus possible and has the potential to improve diagnosis of cerebral aspergillosis. Further prospective studies with larger numbers of patients must be performed to evaluate the clinical significance of Aspergillus PCR with CSF samples.
侵袭性曲霉病(IA)是一种死亡率很高的并发症,尤其是在伴有脑受累的播散性IA中,难以诊断。脑病变活检通常不可行,从脑脊液(CSF)中培养曲霉菌属往往呈阴性。新的分子方法已出现用于诊断IA。到目前为止,仅有少数关于在CSF中检测曲霉DNA的报道。在修改DNA提取方案后,我们通过先前描述的巢式PCR检测法在CSF样本中检测到了曲霉DNA。对6例血液系统恶性肿瘤合并脑曲霉病患者的CSF样本进行了曲霉DNA检测。IA根据欧洲癌症研究与治疗组织/美国国立医学研究院(EORTC/MSG)2002标准进行分类。分别有2例确诊、可能和疑似IA患者。通过巢式PCR对35份CSF样本进行了曲霉DNA检测。巢式PCR检测呈阳性结果的样本通过LightCycler PCR检测法定量。14份CSF样本在巢式PCR检测中呈阳性结果。其中,6份样本在实时PCR中呈阳性结果。每毫升菌落形成单位(CFU)的范围为2,154至63,100,000。每毫升CFU数量最高的是一名急性淋巴细胞白血病合并可能脑曲霉病患者的CSF样本。因此,在CSF样本中检测曲霉DNA是可行的,并且有可能改善脑曲霉病的诊断。必须进行更多患者的进一步前瞻性研究,以评估CSF样本曲霉PCR的临床意义。